Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Abnormal cervical cytology after allogeneic bone marrow transplantation.

Negri G, Herz M, Deola S, Piccin A, Casini M, Babich B, Tauber M, Messini S, Marucci MR, Vittadello F.

Am J Clin Pathol. 2014 Aug;142(2):222-6. doi: 10.1309/AJCP4SKAUS9TOTJX.

2.

Next generation sequencing: new tools in immunology and hematology.

Mori A, Deola S, Xumerle L, Mijatovic V, Malerba G, Monsurrò V.

Blood Res. 2013 Dec;48(4):242-9. doi: 10.5045/br.2013.48.4.242. Epub 2013 Dec 24. Review.

3.

Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.

Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, Longoni D, Pavan F, Masciocchi F, Algarotti A, Micò C, Grassi A, Deola S, Cavattoni I, Gaipa G, Belotti D, Perseghin P, Parma M, Pogliani E, Golay J, Pedrini O, Capelli C, Cortelazzo S, D'Amico G, Biondi A, Rambaldi A, Biagi E.

Biol Blood Marrow Transplant. 2014 Mar;20(3):375-81. doi: 10.1016/j.bbmt.2013.11.033. Epub 2013 Dec 7.

4.

Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.

Mian M, Farsad M, Pescosta N, Casini M, Cavattoni IM, Deola S, Cortelazzo S.

Ann Hematol. 2013 Jan;92(1):121-3. doi: 10.1007/s00277-012-1525-z. Epub 2012 Jul 22. No abstract available.

PMID:
22820997
5.

Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT.

Toffalori C, Cavattoni I, Deola S, Mastaglio S, Giglio F, Mazzi B, Assanelli A, Peccatori J, Bordignon C, Bonini C, Cortelazzo S, Ciceri F, Fleischhauer K, Vago L.

Blood. 2012 May 17;119(20):4813-5. doi: 10.1182/blood-2012-02-411686. No abstract available.

6.

Increased effector-target cell conjugate formation due to HLA restricted specific antigen recognition.

Voss CY, Deola S, Fleisher TA, Marincola FM.

Immunol Res. 2009;45(1):13-24. doi: 10.1007/s12026-008-8041-1.

7.

Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS.

Selleri S, Palazzo M, Deola S, Wang E, Balsari A, Marincola FM, Rumio C.

Int Immunol. 2008 Aug;20(8):961-70. doi: 10.1093/intimm/dxn055. Epub 2008 Jun 10.

8.

GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells.

Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak SL, Rumio C, Panelli MC, Maric D, Stroncek DF, Wang E, Marincola FM.

J Transl Med. 2008 Apr 15;6:17. doi: 10.1186/1479-5876-6-17.

9.

Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions.

Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H, Stroncek D, Wang E, Marincola FM.

J Immunol. 2008 Feb 1;180(3):1362-72.

10.

Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells.

Deola S, Scaramuzza S, Birolo RS, Cergnul M, Ficara F, Dando J, Voena C, Vai S, Monari M, Pogliani E, Corneo G, Peccatori J, Selleri S, Bordignon C, Roncarolo MG, Aiuti A, Bregni M.

J Transl Med. 2007 Jul 12;5:35.

11.

Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets.

Jin P, Wang E, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM.

J Transl Med. 2006 Jun 28;4:26.

12.

Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.

Bregni M, Fleischhauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, Deola S, Scaramuzza S, Re F, Setola E, Monari M, Mazzi B, Servida P, Corradini P, Peccatori J.

Bone Marrow Transplant. 2006 Feb;37(3):311-5.

PMID:
16400340
13.

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.

Stroncek DF, Basil C, Nagorsen D, Deola S, Aricó E, Smith K, Wang E, Marincola FM, Panelli MC.

J Transl Med. 2005 Jun 13;3:24.

14.

Polarized monocyte response to cytokine stimulation.

Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P, Marincola FM, Panelli MC.

Genome Biol. 2005;6(2):R15. Epub 2005 Jan 21.

15.

IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.

Ficara F, Superchi DB, Hernández RJ, Mocchetti C, Carballido-Perrig N, Andolfi G, Deola S, Colombo A, Bordignon C, Carballido JM, Roncarolo MG, Aiuti A.

Mol Ther. 2004 Dec;10(6):1096-108.

PMID:
15564141
16.
17.

Mobilized blood CD34+ cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice.

Deola S, Scaramuzza S, Birolo RS, Carballido-Perrig N, Ficara F, Mocchetti C, Dando J, Carballido JM, Bordignon C, Roncarolo MG, Bregni M, Aiuti A.

Hum Gene Ther. 2004 Mar;15(3):305-11.

PMID:
15018739
18.

Safety of retroviral gene marking with a truncated NGF receptor.

Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, Dinauer M, Sadat M, Aiuti A, Deola S, Radrizzani M, Hagenbeek A, Apperley J, Ebeling S, Martens A, Kolb HJ, Weber M, Lotti F, Grande A, Weissinger E, Bueren JA, Lamana M, Falkenburg JH, Heemskerk MH, Austin T, Kornblau S, Marini F, Benati C, Magnani Z, Cazzaniga S, Toma S, Gallo-Stampino C, Introna M, Slavin S, Greenberg PD, Bregni M, Mavilio F, Bordignon C.

Nat Med. 2003 Apr;9(4):367-9. No abstract available.

PMID:
12669036
19.

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C.

Science. 2002 Jun 28;296(5577):2410-3.

20.

Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells.

Dando JS, Aiuti A, Deola S, Ficara F, Bordignon C.

J Gene Med. 2001 May-Jun;3(3):219-27.

PMID:
11437327
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk